Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:
Shu-Min Yuan
Shu-Min Yuan
Institute of Zoology
China
Kai Gao
Kai Gao
Central South University
China
Dong-Mei Wang
Dong-Mei Wang
Jiangsu Province Hospital
China
Xiong-Zhi Quan
Xiong-Zhi Quan
Kunming Medical University
China
Chuan Qin
Chuan Qin
Institute of Laboratory Animal Science
China
Lian-feng Zhang
Lian-feng Zhang
Peking Union Medical College
China

Acta Pharmacol Sin 2011 Mar 31;32(3):295-302. Epub 2011 Jan 31.

Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing, China.

Aim: To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models.

Methods: The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg(-1)·d(-1) and 100 mg·kg(-1)·d(-1)) groups and an Aricept (2 mg·kg(-1)·d(-1)) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris water-maze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot.

Results: In Morris water-maze test, evodiamine (100 mg·kg(-1)·d(-1)) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg(-1)·d(-1)) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease.

Conclusion: The results indicate that evodiamine (100 mg·kg(-1)·d(-1)) improves cognitive abilities in the transgenic models of Alzheimer's disease.

Download full-text PDF

Source
http://dx.doi.org/10.1038/aps.2010.230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002780PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2011
44 Reads

Publication Analysis

Top Keywords

alzheimer's disease
16
100 mg·kg-1·d-1
16
evodiamine 100
12
transgenic mouse
8
models alzheimer's
8
glucose uptake
8
il-6 tnf-α
8
il-1β il-6
8
appswe/ps1Δe9 transgenic
8
water-maze test
8
morris water-maze
8
samp8 appswe/ps1Δe9
8
evodiamine
7
mg·kg-1·d-1
6
alzheimer's
5
alleviated impairments
4
weeks treatment
4
controls weeks
4
impairments learning
4
samr1 controls
4

References

(Supplied by CrossRef)

Similar Publications